




## Purine Metabolites on HALO® AQ-C18 compared to a Competitor 100% Aqueous Compatible Column



### PEAK IDENTITIES

1. 5-Amino-imidazole-4-carboxamide
2. Azepinomycin
3. Guanine - Substrate
4. 2,6-Diaminopurine
5. Uric Acid
6. Xanthine - Product
7. 8-Azaxanthine
8. 8-Azaguanine
9. Allopurinol

### TEST CONDITIONS:

Column: HALO 90 Å AQ-C18, 2.7 μm, 2.1 x 100 mm  
 Part Number: 92812-622  
 Column: SPP 2.7 μm, 130 Å 100% aqueous compatible C18  
 Mobile Phase A: water/0.1% formic acid  
 Isocratic: 100% A  
 Flow Rate: 0.5 mL/min.  
 Temperature: 35 °C  
 Injection Volume: 1 μL

Wavelength: PDA, 254 nm  
 Flow Cell: 1 μL  
 Data Rate: 40 Hz  
 Response Time: 0.050 sec.  
 LC System: Shimadzu Nexera X2

The HALO 90 Å AQ-C18, 2.7 μm column stands out in its ability to resolve this set of purine metabolites compared to a competitor 100% aqueous compatible C18 SPP column. The molecules are highly polar and are not retained under reversed-phase conditions that include an organic modifier. The HALO 90 Å AQ-C18, 2.7 μm column was chosen for its ability to resolve the highly polar purine metabolites and inhibitors of interest. Under the current use conditions, the AQ-C18 column is stable for many thousands of samples, including tissue homogenates.